Open AccessSecondary T-cell lymphoblastic lymphoma in a child after anticancer therapy for neuroblastoma: clinical case
Author(s) -
Ю. К. Тошина,
Ю. В. Диникина,
А. С. Егоров,
А. И. Смирнова,
М. Б. Белогурова
Publication year - 2020
Publication title -
rossijskij žurnal detskoj gematologii i onkologii
Language(s) - English
Resource type - Journals
eISSN - 2413-5496
pISSN - 2311-1267
DOI - 10.21682/2311-1267-2020-7-2-115-9
Subject(s) - neuroblastoma , medicine , lymphoma , incidence (geometry) , pediatrics , oncology , lymphoblastic lymphoma , lymphoblastic leukemia , leukemia , solid tumor , cancer , immunology , t cell , cell culture , genetics , physics , immune system , optics , biology
Neuroblastoma (NB) is the most common extra-cranial solid tumor in infants with the most heterogeneous clinical course to compare with other malignant diseases. Due to intensive multimodal anticancer treatment there are an increased number of survivors and issues related to long-term effects are becoming increasingly important. One of them is the risk of secondary malignant neoplasms. This article represents a clinical case of T-cell lymphoblastic leukemia in a child aged 2 years and 5 months who received combined antitumor therapy for NB with an intermediate risk group under the age of one year. We observed literature data to investigate the incidence of second malignant neoplasms in patients with NB for the period from 1948 to 2018 and analyzed risk factors.